



World Health  
Organization

**WHO POSITION  
PAPER ON  
MAMMOGRAPHY  
SCREENING**



# **WHO position paper on mammography screening**



**World Health  
Organization**

WHO Library Cataloguing-in-Publication Data

WHO position paper on mammography screening.

1.Mammography. 2.Early Detection of Cancer. 3.Breast Neoplasms – prevention and control. I.World Health Organization.

ISBN 978 92 4 150793 6

(NLM classification: WP 815)

**© World Health Organization 2014**

All rights reserved. Publications of the World Health Organization are available on the WHO website ([www.who.int](http://www.who.int)) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [bookorders@who.int](mailto:bookorders@who.int)).

Requests for permission to reproduce or translate WHO publications –whether for sale or for non-commercial distribution– should be addressed to WHO Press through the WHO website ([www.who.int/about/licensing/copyright\\_form/en/index.html](http://www.who.int/about/licensing/copyright_form/en/index.html)).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Printed in Switzerland

# Contents

<b>Acknowledgements</b>	<b>5</b>
<b>Abbreviations</b>	<b>6</b>
<b>Executive Summary</b>	<b>7</b>
<b>Recommendations by age group and resource setting</b>	<b>11</b>
1. Women aged 50–69 years	11
2. Women aged 40–49 years	12
3. Women aged 70–75 years	12
<b>Introduction</b>	<b>13</b>
<b>Objectives, target audience and scope</b>	<b>15</b>
<b>Development process</b>	<b>16</b>
Review groups	16
Management of conflict of interest	17
Decision-making	17
External review	18
Review of the evidence	18
<b>Evidence and recommendations</b>	<b>20</b>
Evidence of benefits and harms	20
Evidence on screening interval	22
General considerations	22
<b>Recommendations by age and resource setting</b>	<b>27</b>
1. Women aged 50–69 years	27
2. Women aged 40–49 years	29
3. Women aged 70–75 years	30
Research priorities	31
<b>Dissemination and implementation</b>	<b>33</b>
<b>Useful web resources</b>	<b>34</b>
<b>References</b>	<b>35</b>
<b>List of contributors</b>	<b>37</b>
<b>Annex A - Evidence to recommendations template</b>	<b>39</b>
<b>Annex B - Evidence Summary</b>	
<b>Benefits and harms of mammography screening: umbrella systematic review</b>	<b>47</b>
<b>Introduction</b>	<b>49</b>
<b>Methods and data source</b>	<b>50</b>
Table 1. PICO question for the evidence review	51
Systematic reviews included	51
Available mammography randomized controlled trials	52
Areas of controversy	52

<b>Outcome data sources</b>	<b>53</b>
Breast cancer-specific mortality	53
Health-related quality of life, quality of life, disability-adjusted life years	54
Overtreatment	54
Mastectomies	54
Overdiagnosis	54
False positive rate	55
All-cause mortality	55
<b>Evidence profile</b>	<b>56</b>
Table 2. Screening mammography (including data from contemporary observational studies)	56
Table 3. Systematic reviews of randomized controlled trials (RCTs)	59
Table 4. Systematic reviews of observational studies	60
Table 5. Systematic reviews evaluating psychological impact of mammography	63
Table 6. Mammography screening randomized controlled trials	64
Table 7. Convergence of relative estimates of breast cancer mortality across various reviews	65
Table 8. Evidence profile. Breast cancer mortality in randomized controlled trials (median follow-up of about 11 years)	66
Table 9a. Screening interval and breast cancer mortality: data from modelling	67
Table 9b. Screening interval and breast cancer mortality: data from randomized controlled trials	67
Table 10. Evidence profile for treatment type (proportion of women receiving treatment)	68
Table 11. Evidence profile. Mastectomy data from randomized controlled trials (median follow-up of about 11 years)	69
Table 12a. Evidence profile. False positive rate per single screening round in North America	70
Table 12b. Evidence profile. False positive rate per four screening mammographies over 11 years, in North America	70
Table 13. Evidence profile. All-cause mortality (median follow-up of about 11 years), data from randomized trials	71
<b>References</b>	<b>72</b>
<b>Search strategy</b>	<b>75</b>
<b>PRISMA flow diagram and checklist</b>	<b>77</b>

# Acknowledgements

The *World Health Organization position paper on mammography screening* was produced under the overall direction of Dr Oleg Chestnov, Assistant Director-General, Noncommunicable Diseases and Mental Health, and Dr Shanthi Mendis, Director a. i., Management of Noncommunicable Diseases.

Dr Cecilia Sepúlveda, Senior Advisor, Cancer Control WHO, coordinated the overall publication and provided editorial input.

Professor Hassan Murad, Knowledge and Evaluation Unit of the Center for the Science of Healthcare Delivery and the Center for Translational Services Science Activities, Mayo Clinic, USA, conducted the systematic review.

Professor Carl Heneghan of the Centre for Evidence-Based Medicine, Nuffield Department of Primary Care Health Sciences, University of Oxford, United Kingdom was co-chair of the Guideline Development Group meeting on recommendations.

Dr Gerald Gartlehner, GRADE Methodologist and Head of Department for Evidence-based Medicine and Clinical Epidemiology at the Danube University, Krems, Austria, was co-chair of the Guideline Development Group meeting on recommendations. He also provided assistance with the GRADE methodology and evidence during the recommendations process.

David Bramley was rapporteur and writer of these guidelines.

Dr Susan Norris of the WHO Guideline Review Committee secretariat, provided valuable support and guidance throughout the process of guideline development.

External experts and technical staff at WHO headquarters and regional offices, provided valuable input by contributing to and reviewing the drafts (see list of contributors).

